A Clinical Study to Evaluate Enlicitide (MK-0616) Formulations in Healthy Adult Participants (MK-0616-035)
Launched by MERCK SHARP & DOHME LLC · Mar 12, 2025
Trial Information
Current as of April 29, 2025
Recruiting
Keywords
ClinConnect Summary
The clinical trial titled "A Clinical Study to Evaluate Enlicitide (MK-0616) Formulations in Healthy Adult Participants" is researching how different forms of a medication called enlicitide behave in the body of healthy adults. The main goal is to understand how the body absorbs and processes enlicitide over time when given in various forms. This information will help researchers learn which formulation might be the most effective.
To participate in this study, individuals must be healthy, between the ages of 18 to 65 years old, and have a body mass index (BMI) between 18 and 32. Additionally, participants should not smoke or have used any tobacco products for at least three months. Those with certain health issues, like gastrointestinal diseases or a history of cancer, may not be eligible. If you join the trial, you can expect to take the medication in one of its formulations and be monitored over time to see how your body reacts. This study is currently recruiting participants, and your involvement could contribute to important research on this medication.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- The main inclusion criteria include but are not limited to the following:
- • Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior
- • Has body mass index (BMI) ≥18 kg/m\^2 and ≤32 kg/m\^2
- Exclusion Criteria:
- The main exclusion criteria include but are not limited to the following:
- • Has history of gastrointestinal disease which may affect food and drug absorption or has had a gastric bypass or similar surgery
- • Has history of cancer (malignancy)
- • Has positive results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV)
About Merck Sharp & Dohme Llc
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., is a leading global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines and vaccines that address unmet medical needs. With a strong focus on research and development, Merck Sharp & Dohme leverages advanced science and technology to enhance patient outcomes across various therapeutic areas, including oncology, infectious diseases, and cardiovascular health. Committed to ethical practices and regulatory compliance, the company actively engages in clinical trials to advance medical knowledge and improve health care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tempe, Arizona, United States
Patients applied
Trial Officials
Medical Director
Study Director
Merck Sharp & Dohme LLC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported